Asunto(s)
Enfermedad de Crohn/complicaciones , Infarto del Miocardio/etiología , Enfermedades de la Aorta/diagnóstico por imagen , Enfermedad de Crohn/diagnóstico , Humanos , Infarto/diagnóstico por imagen , Riñón/irrigación sanguínea , Masculino , Infarto del Miocardio/terapia , Factores de Riesgo , Bazo/irrigación sanguínea , Trombosis/diagnóstico por imagen , Adulto JovenRESUMEN
AIM: Ozenoxacin is a nonfluorinated quinolone antibacterial approved for topical treatment of impetigo. Because quinolones have known chondrotoxic effects in juvenile animals, the potential toxicity of ozenoxacin was assessed in preclinical studies. MATERIALS & METHODS: Ozenoxacin or ofloxacin (300 mg/kg/day for 5 days, for each compound) was orally administered to juvenile rats, and oral ozenoxacin (10-100 mg/kg/day for 14 days) was administered to juvenile dogs. RESULTS: In juvenile rats, ozenoxacin showed no chondrotoxicity, whereas ofloxacin produced typical quinolone-induced lesions in articular cartilage in three of ten rats. Oral ozenoxacin administration to juvenile dogs showed no chondrotoxicity or toxicologically relevant findings in selected target organs. CONCLUSION: Ozenoxacin was generally well-tolerated in juvenile rats and dogs, with no evidence of quinolone-induced arthropathy.
